Related Experiment Video

Updated: Oct 19, 2026

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Human monoclonal antibodies to MN-24 peptide of gp 120 HIV-1

E Sidorova1

  • 1Institute for Viral Preparations of Russian Academy of Medical Sciences, Moscow, Russia.

Human Antibodies
|July 16, 1999
PubMed

Human monoclonal IgM antibodies to synthetic peptide MN-24 corresponding to 303-325 residues of gp 120 HIV were obtained. Antibodies are made synthetic by CD5+B lymphocytes and are polyspecific: they react not only with different short peptides but with some macromolecular antigens as well. Anti-MN-24 antibodies possess antigen-binding activity but do not possess virus neutralizing activity. It is suggested that anti-MN-24 antibodies belong to the natural antibodies.

More Related Videos

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood13:14

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...